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Abstract
Background: We have previously shown that vitamin D deficiency has a detrimental impact on lung development.
In this study, we aimed to identify the mechanisms linking vitamin D with lung development using a mouse model
of dietary manipulation.
Methods: Female offspring were euthanized at different time-points; embryonic day (E)14.5, E17.5 or postnatal day
(P)7. Lung tissue was collected for mass spectrometry-based proteomic analysis. Label-free quantitation was used
to identify the differentially expressed proteins and ELISA confirmed the expression of selected proteins. Lungs from
separate groups of mice were fixed and processed for stereological assessment of lung structure.
Results: No differences in protein expression between vitamin D deficient and replete mice were detected at
E14.5 and E17.5, whereas 66 proteins were differentially expressed in P7 lungs. The expression of pulmonary
surfactant-associated protein B (SP-B) and peroxiredoxin 5 (PRDX5) were reduced in P7 lungs of vitamin D deficient
mice, while the production of collagen type Ι alpha 1 (COL1A1) was higher in lungs of vitamin D deficient mice. There
were no differences in lung volume, parenchymal volume, volume of airspaces or surface area of airspaces between
vitamin D deficient and vitamin D replete mice across three time-points.
Conclusions: The difference in protein expression during the early postnatal time-point suggests that vitamin
D deficiency may induce alterations of lung structure and function in later life during alveolarization stage
through impaired pulmonary surfactant production and anti-oxidative stress ability as well as enhanced collagen
synthesis. These data provided a plausible mechanism linking maternal vitamin D deficiency with altered postnatal
lung function.
Keywords: Vitamin D deficiency, Proteomic mass spectrometry, Pulmonary surfactant-associated protein B, Collagen
type Ι alpha 1, Lung development
Background
Vitamin D has roles in both skeletal and non-skeletal
health, and vitamin D deficiency is recognized as a
prevalent health problem [1, 2]. A plethora of studies
have shown cross-sectional associations between vitamin
D deficiency and chronic respiratory diseases such as
asthma, chronic obstructive pulmonary disease, and
cystic fibrosis [3–5]. However, these associations are
confounded by the effect of chronic disease on physical
activity levels [6] which are highly correlated with sun
exposure and, therefore, vitamin D synthesis [7]. In line
with this, while studies in animal models have suggested
vitamin D supplementation may ameliorate markers of
chronic lung disease [8, 9], clinical trials using vitamin D
supplementation have been disappointing [10, 11].
While clinical studies have shown no benefit of
vitamin D supplementation in established disease, other
studies have suggested that vitamin D deficiency may
be a precursor to the development of respiratory
disease [12]. For example, maternal vitamin D defi-
ciency is associated with impairments in postnatal lung
function [13, 14] and an increased risk of developing
asthma [15, 16]. In support of this, we have recently
demonstrated that in utero vitamin D deficiency is suf-
ficient to cause deficits in lung structure and function
using a mouse model [17, 18]. Genomic analyses of
lung tissue from mice and humans have identified a
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range of genes that are involved in lung development
[19] that contain vitamin D response elements (VDREs)
[20, 21] suggesting a wide range of roles for vitamin D
in normal lung growth. In addition, in vitro and in vivo
studies have suggested that vitamin D may be involved
in epithelial-mesenchymal interactions [22, 23], calcium
regulation in alveolar type II cells [24] and surfactant
metabolism [25] during lung maturation. Taken to-
gether, these observations suggest that vitamin D is
critical during lung development; however, no study
has assessed the pathways that are directly altered by
vitamin D deficiency during fetal lung development in
vivo.
The aim of this study was to identify lung develop-
ment pathways that are sensitive to vitamin D deficiency.
Specifically, using an established mouse model of vita-
min D deficiency, we aimed to determine if maternal
vitamin D deficiency 1) has an influence on the protein
expression in embryonic and neonatal lungs and 2) re-




A mouse model of vitamin D deficiency was established
by dietary manipulation as described previously [17].
Briefly, three weeks old female BALB/c mice (ARC,
Murdoch, Western Australia) were fed with vitamin
D-deficient (0 vitamin D3) or –replete (2195 IU/kg
vitamin D3) diets (Specialty Feeds, Glen Forrest,
Western Australia) for at least 5 weeks before mating
with replete male mice. The caloric content of these
two diets were similar (deficient, 15.3 MJ/kg; replete
15.8 MJ/kg), and the deficient diets were supple-
mented with calcium 25 g/kg to avoid hypocalcaemia.
Mice were housed in a room with a 12:12 h ultravio-
let B-free light/dark cycle. At key developmental
time-points embryonic day (E)14.5, E17.5 or postnatal
day (P)7, mice were euthanized by overdose with
ketamine: xylazine (800 mg/kg: 40 mg/kg). Lungs of
E14.5, E17.5 and P7 vitamin D deficient and replete
mice were snap frozen in liquid nitrogen for proteomic
analysis or immersion fixed in formalin for histological as-
sessment. We focussed on female mice for these experi-
ments based on our previous study which showed the
female lung is most susceptible to the effects of early life
vitamin D deficiency [17]. To ensure independence of the
analysis each mouse was from a different litter, the sex of
the pups sex was determined by PCR [26]. Following
euthanasia, serum from pregnant dams was collected
by cardiac puncture for assessment of maternal
serum 25-hydroxyvitamin D [25(OH)D] levels using a
25-hydroxyvitammin D EIA kit (Immunodiagnostic
Systems Limited, Boldon, UK) according to the
manufacturer’s instruction. All studies were per-
formed according to the National Health and Medical Re-
search Council (NHMRC) guidelines and were approved
by The University of Tasmania Animal Ethics Committee.
Protein sample preparation
Lungs were homogenized and proteins were extracted
and digested using trypsin according to established
methods [27]. Briefly, the whole lung was homogenized
in denaturation buffer (7 M urea, 2 M thiourea, 30 mM
Tris, pH8.0) with EDTA-Free protease inhibitor cocktail
(Roche, Basel, Swizerland), and rotated for 2 h at 4 °C.
Protein extracts were precipitated with 9 volumes of
ethanol overnight at −20 °C, and protein pellets were
air-dried and resuspended in 200 μl solubilisation buffer
(7 M urea, 2 M thiourea, 30 mM Tris, pH8.0). Protein
concentrations were estimated by Bradford assay and
stored at −80 °C for future use. Protein samples for
liquid chromatography tandem mass spectrometry
(LC-MS/MS) analysis were sequentially incubated in
10 mM dithiothreitol (DTT) overnight at 4 °C and
then 50 mM iodoacetamide incubation for 2 h at 25 °C in
the dark. Proteins were co-precipitated with 1 μg of tryp-
sin overnight at −20 °C in 1 ml of methanol. The trypsin-
protein samples were air-dried and reconstituted in
100 mM ammonium bicarbonate followed by trypsiniza-
tion at 37 °C for 5 h with addition of 1 μg of trypsin after
2 h. Digests were terminated by freezing on dry ice.
Orbitrap mass spectrometry
Protein expression was analysed by nano LC-MS/MS
using a Surveyor HPLC system in line with a LTQ-
Orbitrap XL controlled using XCalibur 2.0 software
(Thermo Fisher Scientific, Waltham, MA, USA). Proto-
cols were based on previously described conditions for
peptide separation and data-dependent MS/MS [28].
The LTQ-Orbitrap XL was controlled using XCalibur
2.0 (Thermo Fisher Scientific, MA, USA) and operated
in data-dependent acquisition mode where survey scans
(m/z 460–2000) were acquired in the Orbitrap at a re-
solving power of 60,000. MS/MS spectra were concur-
rently acquired in the LTQ mass analyser on the eight
most intense ions from the FT survey scan. Unassigned
and singly charged precursor ions were not selected for
fragmentation and 30-s dynamic exclusion (repeat count
1 exclusion list size 500) was used. Fragmentation condi-
tions in the LTQ were: 35 % normalized collision energy,
activation q of 0.25, 30 ms activation time and minimum
ion selection intensity of 3000 counts.
Protein identification and bioinformatics analysis
The LTQ-Orbitrap RAW data files were imported into
MaxQuant software (version 1.5.1.2; http://www.max-
quant.org/). The extracted MS/MS spectra were searched
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against the complete Mus musculus reference prote-
ome (ID 000000589; updated on 02/10/2014) compris-
ing 44,455 protein entries using the Andromeda search
engine. Default group-specific and global parameters for
protein identification were used including specific diges-
tion by trypsin allowing a maximum of two missed cleav-
ages, variable oxidation of methionine and acetylation of
protein amino termini, and fixed carbamidomethylation of
cysteine. The tolerances for first peptide searches were set
to 20 ppm and reduced to 4.5 ppm for the main searches.
A false discovery rate (FDR) of 0.01 was used for peptide-
spectrum matches and protein identification. Normalized
label-free quantitation (LFQ) values were imported from
the MaxQuant ProteinGroups output file for statistical
analysis in the Perseus software package (version 1.5.2.6;
http://perseus-framework.org/). Z-score normalized data
were analysed by principal component analysis (PCA) to
determine if any intrinsic clustering or outliers existed
within the data set. Subsequently, two approaches were
used for identification of differential expression of pro-
teins; 1) based on the subset of proteins detected in all
samples or, 2) based on proteins detected in a minimum
of three biological replicates in one or more treatment
groups where missing LFQ values were statistically im-
puted (based on the distribution of LFQ intensity values).
The differential expression of an individual protein
between vitamin D deficient and replete groups was evalu-
ated by t-tests using FDR adjusted p values.
Enzyme-linked immunosorbent assay (ELISA)
A subset of proteins with biologically plausible links
to altered postnatal lung function was selected for in-
dependent confirmation of expression in lungs to the
proteomic assays using ELISA. Specifically, the pro-
duction of pulmonary surfactant-associated protein B
(SP-B) (CUSABIO, Wuhan, China), collagen type Ι
alpha 1 (COL1A1) (CUSABIO), and peroxiredoxin 6
(PRDX6) (Abcam, Cambridge, United Kingdom) in
tissue homogenates was measured according to the
manufacturer’s instructions. 40 μg of the soluble protein
extract from each lung was loaded into the ELISA. The
absorbance was read at 450 nm or 570 nm using a
spectrophotometer (Spectramax M2; Molecular De-
vices, Sunnyvale, CA, USA).
Western blotting assay
The expression of peroxiredoxin 5 (PRDX5) (Abcam)
and myosin-11 (MYH11) (Abcam) in lung homogenates
was assessed using western blotting assay. 20 μg of the
soluble protein extract from each lung was denatured by
heating the protein at 70 °C for 10 min and size fraction-
ated on Bolt 4–12 % Bis-Tris Plus Gel (Thermo Fisher
Scientific). The protein bands were transferred to polyvi-
nylidene fluoride (PVDF) using iBlot Dry Blotting
System (Thermo Fisher Scientific). Automate immuno-
detection was performed using iBand Western System
(Thermo Fisher Scientific) with 0.587 μg/mL of rabbit
anti-PRDX5 antibody (Abcam) or 2 μg/mL of rabbit
anti-MYH11 antiboy (Abcam) followed by 0.25 μg/mL
of goat anti-rabbit Ig-HRP (Dako, Glostrup Municipality,
Denmark). Chemiluminescent detection was performed
using Immobilon Western Chemiluminescent HRP
Substrate (Millipore, Billerica, MA, USA) and bands
were analysed using Kodak Image Station 4000MM
and Carestream Molecular Imaging Software (Care-
stream Health, Rochester, NY, USA). The amount of
protein present in each sample was determined as the
densitometric density. Glyceraldehyde 3-phophate de-
hydrogenase (GAPDH) was used as a loading control,
and the amount of PRDX5 or MYH11 was normal-
ized to GAPDH, and the results were expressed as
relative density to the standard.
Lung stereology
Lung structure was assessed according to ATS/ERS
guidelines for the quantitative assessment of lung struc-
ture [29] The lungs were immersed in 10 % formalin for
24 h prior to embedding in paraffin at a random orienta-
tion according to IUR principles [30]. The whole lung
was serially sectioned at regular intervals (75 μm,
300 μm, and 400 μm for E14.5, E17.5, and P7 respect-
ively) at a constant thickness (5 μm), with a random
starting point between 0 and the interval thickness.
Sections were stained with haematoxylin-eosin for the
assessment of lung structure. Multistage stratified
sampling was used to estimate morphometric parame-
ters [31], point counting was used to obtain total lung
volume (VL; using the Cavalieri method [32]), paren-
chymal volume (Vp) and volume of the airspace in
the parenchyma (Va). Line and intersection counting
was used to obtain the surface area of airspaces (Sa).
Statistics
Between-group comparisons were made using t-test or
analysis of variance (ANOVA) with Holm-Sidak posthoc
tests. Data were log-transformed where necessary to sat-
isfy the assumptions of the test. Data were analysed in
SigmaPlot (Systat, Erkrath, Germany) and reported as
mean (SD). P values of < 0.05 were considered statisti-
cally significant.
Results
Maternal vitamin D levels
Pregnant dams on the vitamin D deficient diet (n = 11) had
significantly lower serum 25(OH)D levels than the dams
on the vitamin D replete diet (n = 11) (p < 0.001) (Fig. 1).
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Principal components analysis (PCA)
Whole lung protein extracts of vitamin D replete and
deficient lungs (E14.5, n = 6/group; E17.5, n = 6/
group; P7, n = 5/group) were used to perform protein
mass spectrometry. In total, 1160 proteins were de-
tected in the lungs on the basis of one or more MS/
MS spectra matching to mouse peptide sequences.
240 proteins were expressed in all the samples after
data normalization. PCA mapping of the first two
principal components, based on LFQ values, from
lungs of E14.5, E17.5 and P7 time-points showed dis-
tinct clustering based on age and vitamin D status
(Fig. 2). At embryonic stages E14.5 or E17.5, the pro-
files of protein expression from vitamin D deficient
and replete groups overlapped while the vitamin D
deficient and replete mice separated into two distinct
clusters at P7.
Differential protein expression
In line with the PCA, no significant differences in pro-
tein expression between lungs of vitamin D deficient
and replete mice were detected at E14.5 or E17.5 (n = 6/
group). In contrast, 66 proteins were differentially
expressed in P7 lungs of vitamin D deficient mice (n = 5)
compared to vitamin D replete mice (n = 5) (FDR ad-
justed p < 0.05) (Table 1). Based on proteins that were
detected in all samples, there were 8 proteins with in-
creased expression and 29 proteins with decreased ex-
pression in vitamin D deficient P7 lungs compared to
vitamin D replete lungs (Fig. 3a). Based on imputed LFQ
values where proteins detected in a minimum of three
samples in one or more groups, there were 31 proteins
with increased expression and 27 proteins with de-
creased expression in vitamin D deficient P7 lungs com-
pared to vitamin D replete lungs (Fig. 3b).
Validation of protein expression
Based on the proteins that were identified as differen-
tially expressed at P7, we validated the expression of
SP-B, PRDX6, and COL1A1 in the mice lungs using
ELISA and the expression of PRDX5 and MYH11
using western blotting. SP-B was only measured in
E17.5 and P7 mice because there are differentiated
pulmonary epithelial cells capable of producing sur-
factant proteins by E17.5 (but not E14.5) [33]. There
was a significant reduction in SP-B in lungs of vita-
min D deficient mice compared to vitamin D replete
Fig. 1 Maternal vitamin D levels. Serum 25(OH)D levels from vitamin
D replete (white circles) and deficient (black circles) dams. Data are
represented as mean (SD), * indicates p < 0.05, n = 11/group
Fig. 2 Principal components analysis map. Scatter plots of principal component 1 (x-axis) and 2 (y-axis) based on the LFQ values from the LC-MS/
MS for vitamin D replete (white symbols) and vitamin D deficient (black symbols) mice at E14.5 (diamonds, n = 6/group), E17.5 (squares, n = 6/group)
and P7 (circles, n = 5/group)
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Table 1 Lists of differentially expressed proteins
Proteins that were detected in all of the P7 samples Proteins that were detected in at least three P7 samples
Fold change Protein names Gene names Fold change Protein names Gene names
0.97 Lamin-A/C Lmna 3.68 Acidic leucine-rich nuclear phosphoprotein
32 family member B
Anp32b
0.87 Phosphate carrier protein Slc25a3 3.51 Basal cell adhesion molecule Bcam
0.73 Myosin-11 Myh11 3.38 60S ribosomal protein L9 Rpl9
0.65 Sodium/potassium-transporting
ATPase subunit alpha-1
Atp1a1 3.29 Trifunctional enzyme subunit beta Hadhb
0.55 Myosin-14 Myh14 3.21 60S ribosomal protein L5 Rpl5
0.54 Ras-related C3 botulinum toxin
substrate 1/3
Rac1/3 3.02 60S ribosomal protein L4 Rpl4
0.38 Myosin-9 Myh9 2.99 rRNA 2-O-methyltransferase fibrillarin Fbl
0.36 Complement C3 C3 2.70 T-complex protein 1 subunit alpha Tcp1
−0.38 Poly(rC)-binding protein 2 Pcbp2 2.54 Alpha 1 type Ι collagen Col1a1
−0.43 Transketolase Tkt 2.52 Small nuclear ribonucleoprotein Sm D1 Snrpd1
−0.47 Transgelin-2 Tagln2 2.48 26S protease regulatory subunit 4 Psmc1
−0.49 Glutathione S-transferase P 1/2 Gstp1/2 2.46 40S ribosomal protein S16 Rps16
−0.51 Chloride intracellular channel
protein 1
Clic1 2.45 60S ribosomal protein L21 Rpl21
−0.53 26S proteasome non-ATPase
regulatory subunit 13
Psmd13 2.34 Heterogeneous nuclear ribonucleoprotein H2 Hnrnph2
−0.53 Peroxiredoxin-1 Prdx1 2.23 Sarcoplasmic/endoplasmic reticulum
calcium ATPase 2
Atp2a2
−0.55 Prohibitin Phb 2.23 Interleukin enhancer-binding factor 3 Ilf3
−0.59 3-hydroxyacyl-CoA dehydrogenase
type-2
Hsd17b10 2.12 Reticulon-4 Rtn4
−0.59 Protein Niban Fam129a 2.08 Serum paraoxonase/lactonase 3 Pon3
−0.59 Tropomyosin alpha-4 chain Tpm4 1.91 E3 ubiquitin-protein ligase NEDD4 Nedd4
−0.64 Protein DJ-1 Park7 1.78 Plasminogen activator inhibitor 1
RNA-binding protein
Serbp1
−0.68 Complement component 1 Q
subcomponent-binding protein
C1qbp 1.58 RuvB-like 2 Ruvbl2
−0.74 Transcription factor BTF3 Btf3 1.57 Far upstream element-binding protein 1 Fubp1
−0.90 Peroxiredoxin-6 Prdx6 1.53 Aldehyde dehydrogenase, cytosolic 1 Aldh1a7
−0.95 Eukaryotic translation initiation
factor 3 subunit F
Eif3f 1.43 Ribosome-binding protein 1 Rrbp1
−1.01 Proteasome activator complex
subunit 1
Psme1 0.97 Lamin-A/C Lmna
−1.02 Pulmonary surfactant-associated
protein B
Sftpb 0.87 Phosphate carrier protein, mitochondrial Slc25a3
−1.23 Platelet-activating factor acetylhydrolase
IB subunit beta
Pafah1b2 0.86 Surfeit locus protein 4 Surf4
−1.30 GTP-binding nuclear protein Ran Ran 0.54 Myosin-14 Myh14
−1.33 Phosphatidylethanolamine-
binding protein 1
Pebp1 0.54 Ras-related C3 botulinum toxin
substrate 1/3
Rac1/3
−1.34 6-phosphogluconolactonase Pgls 0.38 Myosin-9 Myh9
−1.35 Splicing factor 1 Sf1 0.36 Complement C3 C3
−1.37 Macrophage migration inhibitoryv
factor
Mif −0.38 Poly(rC)-binding protein 2 Pcbp2
−1.37 Apolipoprotein A-IV Apoa4 −0.43 Transketolase Tkt
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mice at P7 (n = 8/group) (p = 0.002) but not at E17.5
(n = 8/group) (p = 0.90) (Fig. 4a). The expression of
COL1A1 increased as the age increased (p < 0.001),
and COL1A1 expression was higher in the lungs of
vitamin D deficient mice compared to vitamin D re-
plete mice (n = 6–9/group) across all three develop-
mental time-points (p = 0.048) (Fig. 4b). There was no
difference in PRDX6 expression in the P7 lungs be-
tween vitamin D replete and vitamin D deficient mice
(n = 9/group) (p = 0.832) (Fig. 4c). However, the
expression of PRDX5 was decreased in P7 lungs of
vitamin D deficient mice compared to P7 lungs of
vitamin D replete mice (n = 9/group) (p = 0.049)
(Fig. 5a). The expression of MYH11 in P7 lungs was
not different between vitamin D replete and vitamin
D deficient mice (n = 9/group) (p = 0.274) (Fig. 5b).
Lung structure
E14.5 represents the pseudoglandular of lung develop-
ment and as such many of the lung sub-structures are
not fully developed [34]. Therefore, Vp, Va and Sa could
not be assessed in the E14.5 lungs. There was no differ-
ence in VL (P = 0.32) (Fig. 6a) between vitamin D defi-
cient and replete mice (n = 6/group) at any age. At E17.5
and P7, there were no differences in Vp (p = 0.22)
(Fig. 6b), Va (p = 0.29) (Fig. 6c) or Sa (p = 0.32) (Fig. 6d)
between the lungs of vitamin D deficient and replete
mice (n = 6/group).
Table 1 Lists of differentially expressed proteins (Continued)
−1.42 Actin-related protein 2/3
complex subunit 4
Arpc4 −0.47 Transgelin-2 Tagln2
−1.45 Cystatin-B Cstb −0.49 Glutathione S-transferase P 1/2 Gstp1/2
−1.71 Peroxiredoxin-5 Prdx5 −0.51 Chloride intracellular channel protein 1 Clic1




−0.59 Tropomyosin alpha-4 chain Tpm4
−0.64 Protein DJ-1 Park7
−0.68 Complement component 1 Q subcomponent-
binding protein, mitochondrial
C1qbp
−0.95 Eukaryotic translation initiation factor
3 subunit F
Eif3f
−1.01 Proteasome activator complex subunit 1 Psme1
−1.02 Pulmonary surfactant-associated protein B Sftpb
−1.23 Platelet-activating factor acetylhydrolase IB
subunit beta
Pafah1b2
−1.31 GTP-binding nuclear protein Ran Ran





−1.37 Macrophage migration inhibitory factor Mif
−1.37 Apolipoprotein A-IV Apoa4
−1.42 Actin-related protein 2/3 complex subunit 4 Arpc4
−1.45 Cystatin-B Cstb
−1.62 Zyxin Zyx
−1.68 2,4-dienoyl-CoA reductase, mitochondrial Decr1
−1.71 Peroxiredoxin-5 Prdx5
−1.72 Transforming growth factor beta-1-induced
transcript 1 protein
Tgfb1i1
−1.94 S100 calcium-binding protein A11 S100a11
−2.00 Transcription factor BTF3 homolog 4 Btf3l4
Differentially expressed proteins in lungs of P7 vitamin D deficient vs. replete mice using two analytical approaches; 1) based on the subset of proteins detected
in all samples or, 2) based on proteins detected in a minimum of three biological replicates in one or more treatment groups where missing LFQ values were
imputed to facilitate the statistical analysis
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Discussion
E14.5, E17.5 and P7 are three key lung development
time-points that represent the pseudoglandular, late can-
alicular/early saccular and alveolar development stages
respectively [35]. This study has clearly shown that ma-
ternal vitamin D deficiency alters protein expression in
the neonatal lung; particularly during the alveolarization
stage of lung development. In addition, maternal vitamin
D deficiency had no observable impact on lung morph-
ology at these three time-points. The differential expres-
sion of proteins SP-B, COL1A1, and PRDX5 in the P7
vitamin D deficient lungs suggests that the expression of
vitamin D sensitive proteins is not evident until later
stages of neonatal lung development. Importantly, SP-B
Fig. 4 Protein validation of SP-B, COL1A1 and PRDX6. The expression of SP-B (a), COL1A1 (b) and PRDX6 (c) in the lungs of vitamin D replete
(white circles) and deficient (black circles) mice assessed by ELISA. Data are represented as mean (SD), * indicates p < 0.05, n = 6/group for E14.5,
n = 8-9/group for E17.5 and P7
Fig. 3 Volcano plots of differentially expressed proteins. Within the proteins that were detected in all P7 samples (a), there were 8 proteins with
increased expression (black circles) and 29 proteins with decreased expression (grey circles) in vitamin D deficient lungs compared to replete lungs
(n = 5/group). Within the proteins that were detected in a minimum of three P7 samples in one or more groups (b), there were 31 proteins with
increased expression (black circles) and 27 proteins with decreased expression (grey circles) in vitamin D deficient lungs compared to replete
lungs (n = 5/group)
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and COL1A1 have biologically plausible associations
with lung structure and function [36, 37], which are
consistent with the postnatal lung function changes as-
sociated with maternal vitamin D deficiency [17, 18].
The reduction in expression of PRDX5, a cytoprotective
antioxidant enzyme [38], in the vitamin D deficient
lung may impair defence against oxidative damage in-
duced by secondary insults. Taken together, these data
suggest that maternal vitamin D deficiency has the po-
tential to impact lung development through reduced
surfactant synthesis, increased collagen deposition, and
impaired anti-oxidative stress response. The potential
role of these proteins in the alteration of lung function
is discussed below.
SP-B is a lipid-associated protein found in lung surfac-
tant which is produced by type 2 alveolar cells and plays
a critical role in the function of pulmonary surfactant
[39]. SP-B rearranges lipid molecules to form a thin
monolayer on the surface of the fluid lining at the gas-
fluid interface which reduces the surface tension and
promotes alveolar inflation [40]. Previous studies have
shown that vitamin D stimulates phosphatidylcholine
(PC) and phosphatidylglycerol (PG) biosynthesis and la-
mellar body release, which are associated with surfactant
synthesis, in fetal rat lungs [25]. Our observations have
shown decreased SP-B protein expression in the P7
lungs of vitamin D deficient mice. Collectively, these
data suggest a critical role for vitamin D in facilitating
normal surfactant function during lung development.
Given the importance of surfactant in reducing com-
pliance and maintaining airway patency [41] and the
association between impaired surfactant function and
Fig. 6 Lung morphometric parameters. Stereological estimation of lung volume (a), parenchymal volume (b), volume of airspaces in the
parenchyma (c), and surface area of the airspaces (d) in the lungs of vitamin D replete (white circles) and deficient (black circles) mice.
Data are represented as mean (SD), n = 6/group
Fig. 5 Protein validation of PRDX5 and MYH11. The relative density of PRDX5 (a) and MYH11 (b) in the lungs of vitamin D replete (white circles)
and deficient (black circles) mice were assessed by western blot. Data are represented as mean (SD), * indicates p < 0.05, n = 9/group
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respiratory disease [42], these observations highlight
the importance of maintaining vitamin D levels dur-
ing lung development. Impairments in surfactant syn-
thesis are entirely consistent with the deficits in lung
function that are associated with maternal vitamin D
deficiency in animal [25] and human studies [43].
Previous studies using mouse models have shown that
one of the key effects of early life vitamin D defi-
ciency is a reduction in lung volume and increased
lung stiffness in P14 mice [17]. In a retrospective ana-
lysis of a longitudinal birth cohort we also demon-
strated that maternal vitamin D deficiency at 16–18
weeks gestation was associated with a reduction in
forced expiratory volume (FVC) [13]. One possible
explanation for these observations is a reduction in
pulmonary surfactant, which is consistent with data
from the present study. Interestingly, in previous birth
cohort study, maternal vitamin D deficiency was mea-
sured at the canalicular stage of human lung develop-
ment while in the present study we found that
vitamin D deficiency was primarily associated with
changes in protein expression at early alveolar stages
of mouse lung development. This may suggest that
the sensitivity of the lung to vitamin D deficiency varies
between mice and humans; although we only measured
vitamin D levels at one time-point during gestation in the
human study and it is entirely possible that the mothers
were deficient throughout gestation. While reduced sur-
factant production is one explanation for the reduction in
lung volume and decreased compliance in early postnatal
lung development [17], it could also be explained by
changes in tissue structural proteins, such as collagen,
which is other major observation in our study.
Collagens are present in major structures of the lung,
and any alterations in quantity, structure, or geometry of
their distribution would be likely to alter the lung func-
tion. Particularly, changes in the interstitium would have
dramatic effects on lung function, where the distance be-
tween air and blood may be as little as 50 nm [44].
COL1A1 encodes collagen type Ι which is a major struc-
tural protein in the lung interstitium and is produced in
large quantities during lung development and during
pathological fibrotic processes [45]. In vitro studies have
shown that the addition of vitamin D reduces the ex-
pression of collagen type Ι [46], and induces an anti-
fibrotic phenotype in various types of cells [23]. In our
study, COL1A1 was increased in lungs of vitamin D de-
ficient mice suggesting that collagen synthesis during
lung development is also sensitive to vitamin D. Again,
this is consistent with the functional defects associated
with maternal vitamin D deficiency that have been de-
scribed previously [17, 18]. It was interesting to note
that differences in COL1A1 were only evident at the P7
time-point from the LC-MS/MS assay, whereas the
ELISA analysis showed that vitamin D deficiency in-
creased the expression of COL1A1 at E14.5, E17.5 and
P7. Notwithstanding this discrepancy, our data suggest
that vitamin D deficiency increases the synthesis of col-
lagen type Ι during early lung development.
Using two differential analysis approaches to analyse
the LC-MS/MS assay data we have identified differential
expression of a range of proteins including peroxidre-
doxin (PRDX) 1, 5, and 6, which were decreased in P7
lungs of vitamin D deficient mice compared to vitamin
D replete mice and myosin (MYH) 9, 11, and 14 were
increased in P7 lungs with vitamin D deficiency. While
we were unable to validate the differential expression of
PRDX6 of MYH11 in independent samples, we are able
to confirm that the expression of PRDX5 was reduced in
the lungs of vitamin D deficient mice at P7. PRDXs are a
family of peroxidases which are present in aerobic or-
ganisms and have an important role in protection of hu-
man tissue from endogenous and exogenous oxidative
damage [47]. PRDXs are classified into typical 2-Cys
(PRDX1-4), atypical 2-Cys (PPXD5), and 1-Cys (PRDX6)
PRDX subfamilies. These enzymes degrade hydrogen
peroxide (H2O2) using their thiol groups of cysteines
(Cys) as catalytic centres [47, 48]. Various studies have
shown the overexpression of PRDXs providing signifi-
cant protection against hyperoxia and apoptosis, and the
deficiency of these enzymes can enhance lipid peroxida-
tion [49–52]. PRDX1, 3, 5, and 6 have prominent and
cell specific expression in human lung tissue [53, 54].
PRDX5 plays a protective role in against oxidative stress
by reducing apoptosis in human tendon cells and lung
carcinoma cells [51, 55]. Furthermore, studies have indi-
cated that PRDX5 has function in maintaining collagen
synthesis and protecting against fibrosis [51, 56], which
is consistent with our finding that overexpression of col-
lagen in lungs of maternal vitamin D deficient mice in
early life may be one of the driven factors of impaired
lung function in later life.
We were unable to confirm the differential expression
of smooth muscle heavy chain MYH11I which we identi-
fied by LC-MS/MS. Given that we did not independently
quantify MYH4 and 9, it is possible that these proteins
do play a role in vitamin D deficiency induced alter-
ations in lung function. In particular, MYH has been
linked to airway smooth muscle contractility [57] which
is consistent with our previous observation that mater-
nal vitamin D deficiency causes increased responsiveness
of the airways to bronchoconstricting agents [18]. The
potential role of MYH in vitamin D deficiency induced
impairments in lung function requires further study.
The lack of difference in lung morphology between
vitamin D deficient and replete mice across these three
developmental time-points that we have shown in this
study suggests that vitamin D deficiency has little impact
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on gross lung structure during the early stages of lung
development. In contrast, our previous findings have
shown that lung volume is reduced in P14 mice that
were vitamin D deficient in utero [17] while parenchy-
mal volume and the volume of the air in the alveolar
ducts are reduced in adult vitamin D deficient mice [18].
This is, however, consistent with the observation that
differences in protein expression were not evident until
later in lung development and it may be that these dif-
ferences in protein expression take time to manifest into
structural differences at the whole organ level.
This study had some limitations that should be ac-
knowledged. Firstly, as with any complex tissue, the
depth of proteome coverage is limited to the most
abundant proteins. However, when working with small
quantities of embryonic tissue there are practical limi-
tations to sample fractionation for lower abundance
protein detection. Secondly, because we used whole
lung homogenates we are unable to comment on the
cell specific differences in protein expression. Thirdly,
in this study we only used lungs from female off-
spring due to the fact that females are more sensitive
to the effect of vitamin D deficiency on lung develop-
ment [17, 58]. Thus, it is unclear whether the same
effects of vitamin D deficiency on protein expression
are evident in male lungs.
Conclusions
In summary, the lack of difference in protein expression
in prenatal developmental time-points, but differential
protein expression in the early postnatal time-point
suggests that vitamin D deficiency may induce alter-
ations in lung function during alveolarization by altered
surfactant and collagen synthesis. The lack of difference
in lung structure at P7, in contrast to structural alter-
ations at P14 [17], suggests that the effect of early life
vitamin D deficiency on lung structure is not realised
until later in alveolar development. These data provided
a plausible mechanism linking maternal vitamin D defi-
ciency with altered postnatal lung function and high-
light the importance of vitamin D level during normal
lung development.
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